Kenvue /$KVUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kenvue
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
Ticker
$KVUE
Sector
Primary listing
NYSE
Employees
22,000
Headquarters
Website
Kenvue Metrics
BasicAdvanced
$35B
24.50
$0.74
0.79
$0.82
4.58%
Price and volume
Market cap
$35B
Beta
0.79
52-week high
$25.17
52-week low
$17.15
Average daily volume
23M
Dividend rate
$0.82
Financial strength
Current ratio
0.978
Quick ratio
0.568
Long term debt to equity
66.664
Total debt to equity
81.491
Dividend payout ratio (TTM)
110.79%
Interest coverage (TTM)
6.83%
Profitability
EBITDA (TTM)
3,357
Gross margin (TTM)
57.88%
Net profit margin (TTM)
9.37%
Operating margin (TTM)
19.40%
Effective tax rate (TTM)
27.98%
Revenue per employee (TTM)
$690,000
Management effectiveness
Return on assets (TTM)
6.85%
Return on equity (TTM)
13.56%
Valuation
Price to earnings (TTM)
24.497
Price to revenue (TTM)
2.294
Price to book
3.24
Price to tangible book (TTM)
-4.6
Price to free cash flow (TTM)
21.35
Free cash flow yield (TTM)
4.68%
Free cash flow per share (TTM)
0.849
Dividend yield (TTM)
4.54%
Forward dividend yield
4.58%
Growth
Revenue change (TTM)
-2.16%
Earnings per share change (TTM)
28.77%
What the Analysts think about Kenvue
Analyst ratings (Buy, Hold, Sell) for Kenvue stock.
Bulls say / Bears say
Kenvue’s Q2 2025 adjusted EPS of $0.29 exceeded the $0.28 analyst consensus, demonstrating profitability strength amid industry headwinds. (Reuters)
The board is considering divesting underperforming skin health and beauty brands in a process led by Goldman Sachs that could generate over $500 million to refocus on core high-margin assets. (Reuters)
Governance was strengthened by appointing Starboard Value CEO Jeffrey Smith and two independent directors to Kenvue’s board, enhancing oversight and aligning shareholder interests. (Bloomberg)
In Q4 2024, Kenvue’s organic sales grew just 1.7%, missing the 3.4% consensus estimate and underscoring weak volumes across key categories. (Bloomberg)
Kenvue’s skin-health and beauty segment saw sales slump 7.3% to $977 million in Q1 2025, significantly underperforming analyst expectations and dragging on overall revenue growth. (Reuters)
The company’s 2025 adjusted EPS guidance of $1.00–$1.05 falls short of the $1.13 Wall Street consensus, indicating potential full-year earnings underperformance. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Kenvue Financial Performance
Revenues and expenses
Kenvue Earnings Performance
Company profitability
Kenvue News
AllArticlesVideos
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Market Watch5 days ago
Kenvue CEO lobbied RFK Jr. not to cite Tylenol as autism cause, WSJ reports
Reuters5 days ago
The CEO of Tylenol maker Kenvue lobbied RFK Jr. to not cite the over-the-counter medication as a potential cause of autism in a soon-to-be released report
WSJ5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kenvue stock?
Kenvue (KVUE) has a market cap of $35B as of September 17, 2025.
What is the P/E ratio for Kenvue stock?
The price to earnings (P/E) ratio for Kenvue (KVUE) stock is 24.5 as of September 17, 2025.
Does Kenvue stock pay dividends?
Yes, the Kenvue (KVUE) stock pays dividends to shareholders. As of September 17, 2025, the dividend rate is $0.8225 and the yield is 4.58%. Kenvue has a payout ratio of 110.79% on a trailing twelve-month basis.
When is the next Kenvue dividend payment date?
The next Kenvue (KVUE) dividend payment date is unconfirmed.
What is the beta indicator for Kenvue ?
Kenvue (KVUE) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.